New research published in Science magazine will guide the development of more effective COVID-19 antibody therapies and help scientists develop effective vaccines to address emerging viral variants.
“We were able to map the geography of Spike and understand which antibodies bind to which footprints. This map provides a reference to help predict which antibodies are still effective against SARS-CoV-2 variants of concern like the currently surging Delta variant,” says LJI Professor Erica Ollmann Saphire, Ph.D., who leads the global effort behind this research, called the Coronavirus Immunotherapeutic Consortium (CoVIC).
CoVIC is a global, academic-industry, non-profit research collaboration that brings together scientists from around the world to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2, and to streamline and accelerate the research pipeline for antibody-based therapeutics needed against SARS-CoV-2. GHR joined the Bill & Melinda Gates Foundation and the National Institutes of Health (NIH) in supporting the global partnership, headquartered at the La Jolla Institute for Immunology (LJI).
Learn more here.